 Jason Hoppe
Concepts (169)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Analgesics, Opioid | 22 | 2023 | 783 | 4.580 |
Why?
| | Prescription Drug Monitoring Programs | 6 | 2023 | 13 | 3.170 |
Why?
| | Emergency Service, Hospital | 31 | 2023 | 1829 | 3.090 |
Why?
| | Opioid-Related Disorders | 8 | 2022 | 422 | 1.950 |
Why?
| | Practice Patterns, Physicians' | 14 | 2023 | 1180 | 1.860 |
Why?
| | Decision Support Systems, Clinical | 4 | 2023 | 179 | 1.750 |
Why?
| | Buprenorphine | 5 | 2022 | 138 | 1.670 |
Why?
| | Back Pain | 4 | 2023 | 44 | 1.460 |
Why?
| | Pain | 4 | 2023 | 712 | 1.120 |
Why?
| | Prescription Drugs | 5 | 2017 | 116 | 1.090 |
Why?
| | Naloxone | 2 | 2021 | 99 | 0.840 |
Why?
| | Drug Overdose | 5 | 2021 | 296 | 0.790 |
Why?
| | Electronic Health Records | 3 | 2023 | 805 | 0.770 |
Why?
| | Emergency Medicine | 2 | 2022 | 227 | 0.770 |
Why?
| | Narcotic Antagonists | 6 | 2022 | 139 | 0.720 |
Why?
| | Pain Management | 3 | 2017 | 291 | 0.590 |
Why?
| | Drug Prescriptions | 4 | 2023 | 241 | 0.560 |
Why?
| | Attitude of Health Personnel | 3 | 2020 | 990 | 0.540 |
Why?
| | Drug Monitoring | 2 | 2017 | 184 | 0.540 |
Why?
| | Substance Abuse Detection | 2 | 2014 | 62 | 0.490 |
Why?
| | Controlled Substances | 1 | 2014 | 2 | 0.490 |
Why?
| | Physicians | 2 | 2020 | 776 | 0.470 |
Why?
| | Pharmacies | 1 | 2014 | 33 | 0.470 |
Why?
| | Opiate Substitution Treatment | 4 | 2022 | 102 | 0.440 |
Why?
| | Prescriptions | 2 | 2023 | 60 | 0.440 |
Why?
| | Drug-Seeking Behavior | 1 | 2013 | 22 | 0.440 |
Why?
| | Cannabinoids | 3 | 2020 | 116 | 0.410 |
Why?
| | Humans | 43 | 2023 | 115587 | 0.400 |
Why?
| | Pharmacists | 1 | 2014 | 237 | 0.400 |
Why?
| | Retrospective Studies | 14 | 2023 | 12608 | 0.360 |
Why?
| | Patient Discharge | 1 | 2016 | 770 | 0.350 |
Why?
| | Adult | 20 | 2022 | 30718 | 0.320 |
Why?
| | Abdominal Pain | 3 | 2019 | 135 | 0.310 |
Why?
| | Marijuana Abuse | 2 | 2020 | 209 | 0.290 |
Why?
| | Drug Packaging | 2 | 2017 | 43 | 0.280 |
Why?
| | Male | 23 | 2022 | 55949 | 0.270 |
Why?
| | Cross-Sectional Studies | 8 | 2021 | 4435 | 0.270 |
Why?
| | Middle Aged | 13 | 2020 | 26999 | 0.250 |
Why?
| | Female | 21 | 2020 | 59913 | 0.240 |
Why?
| | Academic Medical Centers | 2 | 2017 | 414 | 0.230 |
Why?
| | Delivery of Health Care | 2 | 2021 | 844 | 0.230 |
Why?
| | Vomiting | 3 | 2020 | 125 | 0.220 |
Why?
| | Capsaicin | 2 | 2020 | 28 | 0.210 |
Why?
| | Young Adult | 8 | 2019 | 10470 | 0.200 |
Why?
| | Prescription Drug Misuse | 1 | 2022 | 38 | 0.190 |
Why?
| | Quality Indicators, Health Care | 1 | 2023 | 287 | 0.190 |
Why?
| | Certification | 1 | 2020 | 90 | 0.170 |
Why?
| | Patient Handoff | 1 | 2020 | 27 | 0.170 |
Why?
| | Antiemetics | 1 | 2019 | 32 | 0.170 |
Why?
| | Ketorolac | 1 | 2019 | 17 | 0.170 |
Why?
| | Infection Control | 1 | 2020 | 136 | 0.170 |
Why?
| | Haloperidol | 1 | 2019 | 35 | 0.160 |
Why?
| | Drug Storage | 2 | 2017 | 58 | 0.160 |
Why?
| | Social Work | 1 | 2020 | 75 | 0.160 |
Why?
| | United States | 7 | 2021 | 12295 | 0.160 |
Why?
| | Risk Factors | 4 | 2023 | 8697 | 0.160 |
Why?
| | Poisoning | 2 | 2017 | 110 | 0.160 |
Why?
| | Benzodiazepines | 2 | 2017 | 115 | 0.160 |
Why?
| | Referral and Consultation | 2 | 2021 | 646 | 0.160 |
Why?
| | Automobile Driving | 1 | 2020 | 129 | 0.160 |
Why?
| | Acetaminophen | 2 | 2011 | 237 | 0.150 |
Why?
| | Accidents, Home | 1 | 2017 | 29 | 0.140 |
Why?
| | Medical Staff, Hospital | 1 | 2017 | 74 | 0.140 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 301 | 0.140 |
Why?
| | Logistic Models | 3 | 2017 | 1856 | 0.130 |
Why?
| | Marijuana Smoking | 1 | 2019 | 224 | 0.130 |
Why?
| | Pharmacovigilance | 1 | 2015 | 14 | 0.130 |
Why?
| | Drug Utilization | 2 | 2014 | 167 | 0.130 |
Why?
| | Odds Ratio | 2 | 2017 | 962 | 0.130 |
Why?
| | Inappropriate Prescribing | 1 | 2016 | 52 | 0.130 |
Why?
| | Cohort Studies | 2 | 2016 | 4944 | 0.130 |
Why?
| | Pandemics | 2 | 2021 | 1334 | 0.130 |
Why?
| | Aged | 8 | 2020 | 19251 | 0.130 |
Why?
| | Prospective Studies | 3 | 2023 | 6264 | 0.130 |
Why?
| | Codeine | 1 | 2015 | 7 | 0.130 |
Why?
| | Guideline Adherence | 2 | 2017 | 497 | 0.130 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 69 | 0.130 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 344 | 0.130 |
Why?
| | Coronavirus Infections | 1 | 2020 | 336 | 0.130 |
Why?
| | Hydrocodone | 1 | 2015 | 15 | 0.130 |
Why?
| | Self Report | 2 | 2020 | 698 | 0.120 |
Why?
| | Medication Reconciliation | 1 | 2015 | 25 | 0.120 |
Why?
| | Medication Errors | 1 | 2015 | 89 | 0.120 |
Why?
| | Urban Population | 1 | 2017 | 405 | 0.120 |
Why?
| | Health Services Accessibility | 1 | 2021 | 771 | 0.120 |
Why?
| | Oxycodone | 1 | 2015 | 44 | 0.120 |
Why?
| | Indazoles | 1 | 2014 | 58 | 0.110 |
Why?
| | Adolescent | 6 | 2019 | 17889 | 0.110 |
Why?
| | Antipsychotic Agents | 2 | 2019 | 183 | 0.110 |
Why?
| | Chronic Pain | 1 | 2016 | 210 | 0.110 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 242 | 0.110 |
Why?
| | Aged, 80 and over | 4 | 2019 | 6417 | 0.110 |
Why?
| | Respiratory Insufficiency | 1 | 2016 | 292 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 376 | 0.100 |
Why?
| | Cooperative Behavior | 1 | 2014 | 390 | 0.100 |
Why?
| | Hospitalization | 1 | 2020 | 1765 | 0.100 |
Why?
| | Colorado | 3 | 2019 | 4113 | 0.100 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 9 | 0.090 |
Why?
| | Curriculum | 1 | 2016 | 852 | 0.090 |
Why?
| | Fractures, Bone | 1 | 2015 | 372 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1405 | 0.080 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2011 | 117 | 0.080 |
Why?
| | Acetylcysteine | 1 | 2010 | 144 | 0.080 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 84 | 0.080 |
Why?
| | Cardiovascular System | 1 | 2009 | 124 | 0.070 |
Why?
| | Antidotes | 1 | 2009 | 135 | 0.070 |
Why?
| | Prescription Drug Overuse | 2 | 2017 | 11 | 0.070 |
Why?
| | Consensus | 2 | 2021 | 532 | 0.070 |
Why?
| | Nausea | 2 | 2019 | 103 | 0.060 |
Why?
| | Length of Stay | 2 | 2020 | 958 | 0.060 |
Why?
| | Medical History Taking | 2 | 2015 | 114 | 0.060 |
Why?
| | Nonprescription Drugs | 2 | 2015 | 68 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2019 | 3022 | 0.050 |
Why?
| | Wisconsin | 1 | 2020 | 91 | 0.040 |
Why?
| | Community Health Workers | 1 | 2020 | 46 | 0.040 |
Why?
| | Organizational Innovation | 1 | 2020 | 132 | 0.040 |
Why?
| | Administration, Topical | 1 | 2019 | 137 | 0.040 |
Why?
| | Data Collection | 1 | 2022 | 636 | 0.040 |
Why?
| | Syndrome | 1 | 2019 | 339 | 0.040 |
Why?
| | Risk Assessment | 2 | 2017 | 2987 | 0.040 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 255 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 254 | 0.040 |
Why?
| | Health Transition | 1 | 2016 | 7 | 0.030 |
Why?
| | Tertiary Care Centers | 1 | 2017 | 127 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 4665 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2017 | 499 | 0.030 |
Why?
| | Focus Groups | 1 | 2017 | 393 | 0.030 |
Why?
| | Plant Preparations | 1 | 2015 | 23 | 0.030 |
Why?
| | Child Behavior | 1 | 2017 | 218 | 0.030 |
Why?
| | Analgesics | 1 | 2016 | 157 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2016 | 248 | 0.030 |
Why?
| | Health Care Surveys | 1 | 2016 | 538 | 0.030 |
Why?
| | Hospitals, Teaching | 1 | 2014 | 103 | 0.030 |
Why?
| | Vitamins | 1 | 2015 | 151 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2017 | 478 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2016 | 1227 | 0.030 |
Why?
| | Qualitative Research | 1 | 2017 | 971 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2016 | 1440 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2800 | 0.030 |
Why?
| | Eating | 1 | 2014 | 346 | 0.020 |
Why?
| | Program Evaluation | 1 | 2016 | 836 | 0.020 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2015 | 458 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 308 | 0.020 |
Why?
| | Decision Making | 1 | 2017 | 791 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 41 | 0.020 |
Why?
| | Aging | 1 | 2020 | 1631 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 2907 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 204 | 0.020 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 22 | 0.020 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 17 | 0.020 |
Why?
| | Aripiprazole | 1 | 2009 | 17 | 0.020 |
Why?
| | Risperidone | 1 | 2009 | 26 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 374 | 0.020 |
Why?
| | Thiazoles | 1 | 2009 | 110 | 0.020 |
Why?
| | Quality Improvement | 1 | 2016 | 958 | 0.020 |
Why?
| | Safety | 1 | 2010 | 298 | 0.020 |
Why?
| | Child | 2 | 2017 | 18488 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 962 | 0.020 |
Why?
| | Quinolones | 1 | 2009 | 97 | 0.020 |
Why?
| | Anaphylaxis | 1 | 2010 | 148 | 0.020 |
Why?
| | Piperazines | 1 | 2009 | 314 | 0.020 |
Why?
| | Internship and Residency | 1 | 2016 | 951 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 1870 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2009 | 684 | 0.020 |
Why?
| | Infant | 1 | 2017 | 7979 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 9133 | 0.010 |
Why?
| | Prognosis | 1 | 2011 | 3339 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2010 | 9159 | 0.010 |
Why?
|
|
Hoppe's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|